Prognostic role of sarcopenia and effect of SGLT2-inhibitors on MACE in heart failure patients

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Giuseppe Armentaro

University Hospital Renato Dulbecco, Catanzaro (Italy)

4 More presentations in this session

Presentation thumbnail

Sepsis-induced cardiac dysfunction: echocardiographic patterns and outcome implications

Doctor C. Paraschiv (Bucharest, RO)

Abstract Slides Video

Presentation thumbnail

Impact of left ventricular ejection fraction on outcomes in non-ST-segment elevation myocardial infarction patients with and without chronic kidney disease

Professor Y. Kim (Chuncheon, KR)

Abstract Slides Video

Presentation thumbnail

The Healthcare Amyloidosis European Registry (HEAR): study design and methods

Professor P. Reant (Bordeaux, FR) Professor T. Damy (Creteil, FR)

Abstract Slides Video

Presentation thumbnail

Factors influencing the quality of life in patients with heart failure and its impact on mortality: insights from HEROES registry

Mr A. Bednarek (Warsaw, PL)

Abstract Slides Video

Access the full session

Session thumbnail

Epidemiology, prognosis, and outcome in chronic heart failure (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

The association between sarcopenia and post-discharge outcomes in patients with heart failure: data from the SMILE HF registry

Congress Presentation

Prognostic value of sarcopenia defined by the Sarcopenia Definitions and Outcomes Consortium criteria in patients with heart failure

Congress Presentation

Metabolic profile in subjects with sarcopenic obesity and heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources